公开(公告)号：US20160368965A1

公开(公告)日：2016-12-22

申请号：US15185990

申请日：2016-06-17

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K16/28 ,  A61K51/10 ,  C12N15/115 ,  C12Q1/68 ,  C07K14/705 ,  C12N5/0783 ,  C12P21/02 ,  G01N33/569 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K14/70539 ,  A61K39/0011 ,  A61K51/1027 ,  A61K51/1057 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/4748 ,  C07K14/70503 ,  C07K16/2833 ,  C07K16/303 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/55 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/56977 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract translation: 本发明涉及用于免疫治疗方法的肽，蛋白质，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及单独或与其它肿瘤相关肽组合的肿瘤相关T细胞肽表位，其可以例如用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分或刺激T细胞 离体转移入患者。 与主要组织相容性复合物（MHC）分子结合的肽或本身的肽也可以是抗体，可溶性T细胞受体和其他结合分子的靶标。

公开(公告)号：US20160339092A1

公开(公告)日：2016-11-24

申请号：US15145936

申请日：2016-05-04

Applicant: immatics biotechnologies GmbH

Inventor： Oliver SCHOOR ,  Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/74

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3046 ,  C07K16/3076 ,  C07K2317/34 ,  C12N5/0636 ,  C12N15/1138 ,  C12N2310/16 ,  C12N2501/50

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract translation: 本发明涉及用于免疫治疗方法的肽，蛋白质，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及单独或与其它肿瘤相关肽组合的肿瘤相关T细胞肽表位，其可以例如用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分，或刺激T- 细胞离体转移入患者。 与主要组织相容性复合物（MHC）分子结合的肽或本身的肽也可以是抗体，可溶性T细胞受体和其他结合分子的靶标。

公开(公告)号：US20160287687A1

公开(公告)日：2016-10-06

申请号：US15082876

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Colette SONG

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  C07K14/705 ,  C12N5/0783 ,  A61K35/17

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3038 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/33 ,  C07K2319/55 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract translation: 本发明涉及用于免疫治疗方法的肽，蛋白质，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及单独或与其它肿瘤相关肽组合的肿瘤相关T细胞肽表位，其可以例如用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分或刺激T细胞 离体转移入患者。 与主要组织相容性复合物（MHC）分子结合的肽或本身的肽也可以是抗体，可溶性T细胞受体和其他结合分子的靶标。

公开(公告)号：US20160280758A1

公开(公告)日：2016-09-29

申请号：US15082986

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C07K14/725 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20160279216A1

公开(公告)日：2016-09-29

申请号：US15082978

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: A61K39/00 ,  G01N33/569 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  C07K14/47 ,  C07K14/725

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20160051654A1

公开(公告)日：2016-02-25

申请号：US14934612

申请日：2015-11-06

Applicant: Immatics biotechnologies GmbH

Inventor： Harpreet SINGH ,  Steffen WALTER ,  Toni WEINSCHENK ,  Norbert HILF ,  Oliver SCHOOR ,  Claudia TRAUTWEIN

IPC: A61K39/00 ,  C12N9/10 ,  C07K16/40 ,  C12N5/0783 ,  C07K14/725

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/495 ,  C07K14/7051 ,  C07K16/40 ,  C07K19/00 ,  C07K2317/34 ,  C07K2319/00 ,  C12N5/0638 ,  C12N9/0036 ,  C12N9/13 ,  C12N2502/1157 ,  C12Y208/02011

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.

Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。

公开(公告)号：US20150125478A1

公开(公告)日：2015-05-07

申请号：US14562156

申请日：2014-12-05

Applicant: immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Claudia TRAUTWEIN ,  Norbert HILF ,  Steffan WALTER ,  Harpreet SINGH

IPC: C07K7/08 ,  G01N33/574 ,  A61K39/00 ,  C07K7/06 ,  A61K35/17

CPC classification number: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽的组合。 本发明涉及可以用于引发抗肿瘤免疫应答的疫苗组合物中的来自人类肿瘤细胞的HLA I类和II类分子的30个肽序列及其变体。

公开(公告)号：US20150125477A1

公开(公告)日：2015-05-07

申请号：US14531472

申请日：2014-11-03

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Sabrina KUTTRUFF-COQUI ,  Toni WEINSCHENK ,  Jens FRITSCHE ,  Steffen WALTER ,  Norbert HILF ,  Oliver SCHOOR ,  Colette SONG ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12Q1/68 ,  A61K35/14 ,  C07K16/28 ,  C07K7/06 ,  C07K14/74

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽的组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的肽序列及其变体。

公开(公告)号：US20250092104A1

公开(公告)日：2025-03-20

申请号：US18955513

申请日：2024-11-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Annika SONNTAG ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH ,  Colette SONG

IPC: C07K14/47 ,  A61K38/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250066422A1

公开(公告)日：2025-02-27

申请号：US18936387

申请日：2024-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/06 ,  C07K14/725 ,  C12N5/0783 ,  C12N9/64

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.